Atara Biotherapeutics Inc at Citi BioPharma Conference (Virtual) Transcript

Sep 09, 2021 / 02:40PM GMT
Yigal Dov Nochomovitz - Citigroup Inc., Research Division - Director

Okay. Great. Welcome, everyone. I'm Yigal Nochomovitz. I'm one of the biotech analysts here at Citi. Welcome to the panel on Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy. And it's my great pleasure to have with me today from Atara Bio, Pascal Touchon, who's the President and CEO; from Caribou Biosciences that recently went public, Rachel Haurwitz, President and CEO; from Cellectis, Andre Choulika, the CEO; and from Gracell Bio, William Cao, the Chairman and CEO. So welcome all of you today. Thank you very much for taking the time.

Questions and Answers:

Yigal Dov Nochomovitz - Citigroup Inc., Research Division - Director

I think as a starting point for those less familiar with each of your companies, maybe we could just go through and do a brief introduction to the company and the pipeline and maybe comment as well on what you see as the strengths and differentiating qualities of your cell therapy platform. So maybe, Andre, you want to kick
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot